SCM
MLTX icon

Superstring Capital Management’s MoonLake Immunotherapeutics MLTX Stock Holding History

Superstring Capital Management’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-17,623
Closed -$832K – 39
2025
Q2 		$832K Sell
17,623
-14,522
-45% -$592K 0.98% 27
2025
Q1 		$1.26M Buy
+32,145
New +$1.39M 1.49% 21

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Superstring Capital Management's MLTX Position: Q3 2025 in Review

Superstring Capital Management sold out of MoonLake Immunotherapeutics (MLTX) in Q3 2025, closing a stake of 17,623 shares — an estimated $832K sold.

Superstring Capital Management first reported a position in MLTX in Q1 2025 and held it in 2 quarters. The position peaked at $1.26M in Q1 2025. 134 funds tracked by Wall St. Rank hold MLTX as of Q3 2025.

  • Superstring Capital Management reported no remaining MoonLake Immunotherapeutics position as of Q3 2025 after selling out during the quarter.
  • Superstring Capital Management sold 17,623 MoonLake Immunotherapeutics shares in Q3 2025, an estimated $832K.
  • Superstring Capital Management first reported a position in MoonLake Immunotherapeutics in Q1 2025 and held it in 2 quarters.
  • Superstring Capital Management's MoonLake Immunotherapeutics position peaked at $1.26M in Q1 2025.
  • 134 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q3 2025.

Based on Superstring Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.